Category - Markets

Markets

Cantor starts MindMed at OW; PT $3

Cantor Fitzgerald launched coverage of MindMed (NASDAQ:MNMD) with an “overweight” rating and price target of $3. The stock closed at 58 cents on Aug. 9. MindMed is an early-stage neuro-innovator developing psychedelic...

August 10, 2022

Markets

Dawson James cuts Mesoblast to neutral on potential capital raise

Dawson James downgraded Mesoblast (NASDAQ:MESO; ASX:MSB) to “neutral” and removed its price target after the stock was halted on Aug. 4 in Australia with news of a proposed private placement and another notice of a halt...

August 8, 2022

Markets

Cantor cuts Galmed to neutral on limited insights into programs

Cantor Fitzgerald downgraded Galmed Pharmaceuticals (NASDAQ:GLMD) to “neutral” from “overweight” and slashed its price target to 70 cents from $5 after the company announced a business update along with financials for...

August 4, 2022

Markets

Research Capital ups Valeo Pharma PT on new drug licensing

Research Capital raised its price target for Valeo Pharma (CSE:VPH) to $1 (Canadian) from 70 cents and maintained a “speculative buy” rating after the company closed a $40-million (U.S.) non-dilutive financing from...

August 2, 2022

Markets

Maxim starts scPharmaceuticals at buy; PT $10

Maxim Group initiated coverage of scPharmaceuticals (NASDQ:SCPH) with a “buy” rating and price target of $10. The stock closed at $4.89 on Aug. 2. scPharmaceuticals is a late-stage pre-commercial company developing...

August 2, 2022

Markets

Cantor starts Clever Leaves at OW; PT $4.50

Cantor Fitzgerald initiated coverage of Clever Leaves Holdings (NASDAQ:CLVR) with an “overweight” rating and $4.50 price target. The stock closed at 92 cents on July 27. “In relative terms, the stock offers better ‘pure...

August 1, 2022

Markets

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Tonix Pharmaceuticals (NASDAQ:TNXP) is collaborating with the Kenya Medical Research Institute to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop Tonix’s TNX-801 as a vaccine...

July 28, 2022

Markets

Cantor downgrades ObsEva on restructuring and likely CRL

Cantor Fitzgerald downgraded ObsEva (NASDAQ:OBSV) to “neutral” from “overweight” and slashed its price target to $1 from $6 after the company announced a corporate restructuring and refocus of its development and...

July 28, 2022

Markets

BTIG starts Keros at buy; PT $80

BTIG launched coverage of Keros Therapeutics (NASDAQ:KROS) with a “buy” rating and $80 price target. The stock closed at $28.53 on July 25. Analyst Julian Harrison writes that following Acceleron’s impressive foray into...

July 26, 2022

Markets

Maxim upgrades Agile on financing and contraceptive tailwind

Maxim Group upgraded Agile Therapeutics (NASDAQ:AGRX) to “buy” from “hold” and set a $1 price target, after the company closed a recent equity offering, enacted austerity measures and refined its commercial efforts. The...

July 26, 2022

Category - Markets

Cantor starts MindMed at OW; PT $3

Dawson James cuts Mesoblast to neutral on potential capital raise

Cantor cuts Galmed to neutral on limited insights into programs

Research Capital ups Valeo Pharma PT on new drug licensing

Maxim starts scPharmaceuticals at buy; PT $10

Cantor starts Clever Leaves at OW; PT $4.50

Tonix to develop vaccine in Kenya against monkeypox, smallpox

Cantor downgrades ObsEva on restructuring and likely CRL

BTIG starts Keros at buy; PT $80

Maxim upgrades Agile on financing and contraceptive tailwind

General

More